Your session is about to expire
← Back to Search
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer (M&M Trial)
N/A
Recruiting
Led By Grant R Williams, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Eligible Conditions
- Sarcopenia
- Colorectal Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Chemotherapy Toxicities (Grade 3 - 5)
Secondary study objectives
Overall Survival
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Find a Location
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor
1,403 Previous Clinical Trials
2,478,035 Total Patients Enrolled
2 Trials studying Sarcopenia
72 Patients Enrolled for Sarcopenia
University of Alabama at BirminghamOTHER
1,656 Previous Clinical Trials
2,444,075 Total Patients Enrolled
3 Trials studying Sarcopenia
207 Patients Enrolled for Sarcopenia
Grant R Williams, MDPrincipal InvestigatorUniversity of Alabama at Birmingham